Evaluation of the effect of the H2 haplotype and CYP3As polymorphisms on the antiplatelet response to clopidogrel given before elective percutaneous coronary intervention.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Clopidogrel (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics; Pharmacogenomic
- 21 Aug 2012 Biomarkers information updated
- 06 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 09 Mar 2007 New trial record.